MYC and autosomal recessive polycystic kidney disease: It was found that treatment of ARPKD mouse models with antisense oligonucleotides targeting c-myc was effective in improving disease symptoms.[44] AVI BioPharma is developing AVI-4126, an antisense oligonucleotide aimed at c-myc mRNA, for the treatment of restenosis, cancer, and polycystic kidney disease.[45] This drug is currently in phase II clinical trials.[45] These findings emphasize the critical role of c-myc in PKD cyst formation and present antisense oligonucleotide targeting of c-myc as a potential new therapeutic strategy.